You just read:

Astellas Submits Supplemental New Drug Application for Mirabegron for Use in Combination with solifenacin succinate 5 mg for the Treatment of Overactive Bladder

News provided by

Astellas Pharma Inc.

Jun 29, 2017, 21:00 ET